Equine pulmonary and systemic haemodynamic responses to endothelin-1 and a selective ET(A) receptor antagonist.

The research article investigates the impact of an endogenous peptide called endothelin-1 (ET-1) on the pulmonary and systemic blood flow in horses. The key finding is that ET-1 causes potent vasoconstriction in these circulations, an effect which seems to be significantly mediated through ET(A) receptors.

Introduction and Hypothesis

• The authors’ hypothesis was drawn from previous studies, stating that a peptide hormone known as endothelin (ET) would cause vasoconstriction (narrowing of blood vessels) in the pulmonary system of horses and that this effect would be driven by ET(A) receptors.

Methodology

• The researchers examined the responses of the pulmonary and systemic circulation of horses to the administration of endothelin-1 (ET-1), a potent endogenous peptide that constricts blood vessels and raises blood pressure.
• The study involved 6 conscious, nonsedated horses at rest, to which three different doses of ET-1 were administered intravenously.

Findings

• The results revealed that ET-1 significantly increased pressures in the pulmonary (PAP) and carotid (CAP) arteries, indicating vasoconstriction. Specifically, the peak increases for PAP and CAP were 79% and 51%, respectively.
• The impact of ET-1 was rapid in PAP but lasted longer in CAP. It also led to a significant decrease in cardiac output and a substantial increase in systemic vascular resistance (SVR).
• Interestingly, Pulmonary vascular resistance (PVR) showed a trend toward increase with the higher doses of ET-1, although not achieving statistical significance.

Use of ET(A) receptor antagonist

• To confirm the role of ET(A) receptors in the observed effects, a selective ET(A) receptor antagonist (TBC11251) was used. This antagonist effectively stopped the responses invoked by ET-1, substantiating the researchers’ hypothesis about the role of the ET(A) receptor in mediating the vasoconstriction.

Conclusion and implications

• The researchers concluded that ET-1 is a potent vasoconstrictive agent in the pulmonary and systemic circulation of horses and that its effects are largely mediated through ET(A) receptors in both circulations.
• These findings suggest that endothelin may play a role in hypertensive conditions in horses, which could pave the way for future research on ET-1 antagonists as potential therapeutic agents in hypertensive equine conditions.